Fig. 1 · Structure

Documents & Downloads

Costunolide

Cat. No. A10240 CAS 553-21-9

Telomerase inhibitor

Costunolide is an Inhibitor of human telomerase activity (IC50 = 65 μM in MCF-7 breast cancer cells). It is described to act as an antioxidant, anti-mycobacterial, anti-inflammatory, and anti-viral, with cytotoxic activity.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

In colorectal cancer cell lysates, costunolide-conjugated beads recovered AKT but not MDM2. Cellular treatment decreased the p-MDM2/MDM2 ratio without a corresponding decrease in p-AKT/AKT in the displayed dose response. These findings support an AKT-associated interaction and signaling effect; they do not establish selective kinase inhibition or a biochemical IC50. [1]

In Bt-549 and MDA-MB-157 breast carcinoma cells, costunolide reduced detyrosinated tubulin after 6 h while preserving the overall α-tubulin network. Viability and PARP controls supported a short-term effect without detectable apoptosis. A resveratrol comparator separated NF-κB reporter inhibition from the tubulin response. [2]

In U937 leukemia cells, 10 μM costunolide increased JNK phosphorylation and lysate-derived JNK activity over a short time course. Mild ERK1/2 activation and unchanged p38 activation were also reported, indicating a model-specific signaling response. [3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
FPTase 20 μM
Telomerase (MDA-MB-231) 65 μM
Telomerase (MCF-7) 90 μM

Cellular Effect

Cell Line Activity Value Description Reference
HL-60 IC50 7.7 μM Cytotoxicity against human HL60 cells after 18 hrs by annexin-V labeling-based flow cytometry [PMID: 22985027]
NALM-6 IC50 65 μM Inhibition of telomerase in human NALM6 cells by TRAP assay 10.1039/C0MD00241K
RAW264.7 IC50 > 50 μM Antiinflammatory activity in mouse RAW264.7 assessed as inhibition of LPS-induced NO production preincubated for 30 mins followed by LPS stimulation measured after 24 hrs by Griess reagent based assay [PMID: 33939429]

Costunolide Research Summary

This section summarizes 4 in vitro studies of Costunolide from 3 published references. In vitro models include HCT-15, HCT-116 and DLD1 colorectal cancer cells and their lysates; Bt-549 and MDA-MB-157 human breast carcinoma cells.

Costunolide In Vitro Studies

Following 6 h pretreatment with 25 μM costunolide, Bt-549 and MDA-MB-157 cells showed fewer microtentacles and reduced reattachment by electrical impedance monitoring. The assays support an in vitro attachment phenotype; they do not establish prevention of metastasis in animals or patients. [2]

AKT enrichment by costunolide beads and cellular signaling

Cell-based study · HCT-15, HCT-116 and DLD1 colorectal cancer cells and their lysates [1]

Costunolide-conjugated beads enriched AKT compared with unconjugated beads; MDM2 was not similarly recovered. Cellular treatment reduced the p-MDM2/MDM2 ratio. Figure 3e did not show a corresponding reduction in p-AKT/AKT. These assays do not establish a purified-enzyme IC50, binding affinity or unique target.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
AKT and MDM2 recovery from cell lysatesQualitative immunoblot enrichment AKT recovered with CTD-Sepharose; no comparable recovery with unconjugated beads; MDM2 negative in the same assay.[1]
p-MDM2(Ser166)/MDM2 and p-AKT(Ser473)/AKT ratiosQualitative dose response p-MDM2/MDM2 decreased; p-AKT/AKT showed no corresponding decrease across 0–10 μM.[1]

Literature-Reported Treatment Conditions

Treatment concentration
0, 2.5, 5 and 10 μM for cellular immunoblots; bead pull-down uses immobilized costunolide, not a soluble treatment dose.
Exposure duration
24 h for Figure 3e cellular immunoblots.
Method
Cell treatment followed by the indicated assays.
Vehicle
DMSO is identified as the cellular control in Methods; final percentage is not specified.
Co-treatment
No combination treatment for selected cellular dose response; unconjugated Sepharose and input lysates provide pull-down controls.
Reported limits
No free-compound concentration or affinity is supplied for the immobilized-bead assay. Figure 3 caption does not specify a replicate count.
Methods and source locations

Compound reported in the paper: Costunolide; Compound label in the paper: CTD

Supports a costunolide-associated AKT interaction and signaling response in these models, without claims of selective direct kinase inhibition.

Methods: Reagents, Western blot assay, Pull-down assay using CNBr–costunolide-conjugated beads; Results Sec23; Figure 3c,e and caption.

AKT and MDM2 recovery from cell lysates: CTD-conjugated versus unconjugated Sepharose 4B pull-down, input lysates and immunoblotting. — Figure 3c; Results Sec23; Methods: Pull-down assay.

p-MDM2(Ser166)/MDM2 and p-AKT(Ser473)/AKT ratios: 24 h cellular treatment followed by phosphoprotein/total-protein immunoblot ratios; β-actin loading control. No bar heights digitized. — Figure 3e, displayed blots/ratio plots and caption.

Detyrosinated tubulin and short-term viability controls

Cell-based study · Bt-549 and MDA-MB-157 human breast carcinoma cells [2]

Costunolide reduced detyrosinated tubulin while overall α-tubulin networks remained visible. No PARP cleavage was detected and short-term viability was retained at the tested concentrations. Resveratrol inhibited the NF-κB reporter without reproducing the tubulin effect, supporting separation of these responses rather than proving a specific enzyme target.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Detyrosinated tubulin and PARP cleavageImmunoblot response 10 and 25 μM reduced detyrosinated tubulin versus vehicle; PARP cleavage not detected.[2]
Detyrosinated and overall α-tubulin filament appearanceQualitative microscopy At 25 μM, detyrosinated filaments were reduced while the overall α-tubulin network remained; colchicine and paclitaxel disrupted overall network appearance.[2]
Short-term viability and NF-κB reporter dissociation controlRelative response versus vehicle Viability was retained; costunolide and resveratrol inhibited stimulated NF-κB reporter activity, but resveratrol did not reduce detyrosinated tubulin.[2]

Literature-Reported Treatment Conditions

Treatment concentration
5, 10 and 25 μM in Figure 1; 10 and 25 μM in Figure 2; 25 μM in Figure 3.
Exposure duration
6 h for tubulin immunoblots, imaging and viability; reporter: 4 h drug exposure followed by 1 h TNF-α stimulation with drug present.
Method
Cell treatment followed by the indicated assays.
Vehicle
0.1% DMSO.
Co-treatment
Costunolide single-agent tubulin and viability assays; TNF-α 100 ng/ml is the reporter stimulus. Parthenolide, resveratrol, colchicine and paclitaxel are separate comparator arms, not costunolide combinations.
Reported limits
Costunolide purity and independent stereochemical analytical validation are not specified in the acquired Methods.
Methods and source locations

Compound reported in the paper: Costunolide; Compound label in the paper: Cost

Short-term cellular tubulin phenotype; no direct tubulin-carboxypeptidase inhibition or clinical safety claim.

Methods: Cell culture and chemical compounds, Immunoblot, NF-κB activation, Cell viability, Indirect immunofluorescence; Figures 1–3 and captions; Results first three subsections.

Detyrosinated tubulin and PARP cleavage: Immunoblots normalized to α-tubulin; Figure 1 caption: N=3 Bt-549 and N=6 MDA-MB-157 experiments; mean densitometry ± SD. Caption significance symbols *P<0.05, **P<0.001, t-test. — Figure 1a and caption; first Results subsection. No exact effect sizes inferred.

Detyrosinated and overall α-tubulin filament appearance: Indirect immunofluorescence after 6 h, vehicle and separate drug controls. — Figure 3a–b and caption; Methods: Indirect immunofluorescence.

Short-term viability and NF-κB reporter dissociation control: Six-hour metabolic viability assay; stimulated reporter with separate resveratrol comparator. Methods report mean ± SD of triplicate samples; this does not specify biological replicates. — Figure 2a–b and caption; Figure 1a for resveratrol tubulin control; corresponding Methods and Results.

Microtentacles and tumor-cell reattachment

Cell-based study · Suspended and replated Bt-549 and MDA-MB-157 human breast carcinoma cells [2]

Costunolide reduced microtentacle frequency and subsequent attachment measured by electrical impedance. Resveratrol and paclitaxel did not significantly reduce microtentacle frequency and did not reproduce costunolide’s attachment inhibition. These are cell-based functional endpoints, not an animal metastasis test.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Frequency of cells with microtentaclesBlind scoring, mean ± SD Significantly lower than vehicle (P<0.001 as stated in Results); resveratrol and paclitaxel had no significant effect.[2]
Cell-substratum attachmentCell index (relative electrical impedance) Costunolide reduced attachment compared with vehicle in both cell lines; resveratrol and paclitaxel did not reproduce this reduction.[2]

Literature-Reported Treatment Conditions

Treatment concentration
25 μM costunolide.
Exposure duration
6 h pretreatment; drug remained present during suspension scoring and reattachment. Scoring at 15–30 min after detachment; impedance monitored for 3.5 h.
Method
Cell treatment followed by the indicated assays.
Vehicle
0.1% DMSO.
Co-treatment
Single-agent costunolide versus vehicle and separate comparator drugs.
Reported limits
No exact percentage reduction or attachment rate is extracted from plotted curves.
Methods and source locations

Compound reported in the paper: Costunolide; Compound label in the paper: Cost

Supports decreased microtentacle frequency and in vitro reattachment in two breast cancer cell lines.

Methods: Live cell imaging and microtentacle scoring, Cell-electrode impedance attachment assay; Figures 4–5 and captions; final two Results subsections.

Frequency of cells with microtentacles: Six independent experiments; at least 100 cells scored blindly per experiment; Figure 4 caption uses *P<0.05, **P<0.001, t-test. — Figure 4a–b and caption; Results: Parthenolide and costunolide decrease microtentacle frequency.

Cell-substratum attachment: Real-time xCELLigence monitoring; representative curve is mean ± SD of triplicate wells; three independent experiments reported. — Figure 5 and caption; Methods: Cell-electrode impedance attachment assay. No exact curve values extracted.

JNK activation after costunolide exposure

Cell-based study · U937 human promonocytic leukemia cells [3]

Costunolide increased JNK phosphorylation and lysate-derived JNK activity. The Results report mild ERK1/2 activation and no p38 activation, qualifying the broader abstract wording. This experiment measures a cellular response, not direct binding of costunolide to JNK.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
JNK phosphorylation and kinase activityQualitative time course JNK phosphorylation peaked at 60 min; kinase activity increased at 30 and 60 min. p38 activation was unchanged; ERK1/2 activation increased mildly at 60 and 120 min.[3]

Literature-Reported Treatment Conditions

Treatment concentration
10 μM.
Exposure duration
15–120 min for phosphoprotein time course; 30 and 60 min increases in kinase activity.
Method
Cell treatment followed by the indicated assays.
Vehicle
Untreated/time-zero controls; treatment vehicle is not specified in the acquired cellular methods.
Co-treatment
Costunolide alone in the selected time course.
Reported limits
No numerical fold changes are extracted from bands.
Methods and source locations

Compound reported in the paper: Costunolide; Compound label in the paper: Costunolide

U937 cellular JNK response only; no animal efficacy or dosing claim.

pp.1803–1805: Materials, cellular and kinase methods, Results first subsection, Figure 1a–b and caption.

JNK phosphorylation and kinase activity: Phospho/total MAPK immunoblots and lysate-derived c-Jun phosphorylation assay. Figure 1 is representative of three separate experiments. — p.1804 Results first subsection; p.1805 Figure 1a–b/caption; p.1804 In Vitro Kinases Assay.

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 553-21-9
Applications Telomerase inhibitor
Formula C15H20O2
Molecular Weight 232.3
SMILES
CC1=CCC/C(=C/[C@@H]2[C@@H](CC1)C(=C)C(=O)O2)/C

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 43 mg/mL (185.08 mM)
Water Insoluble
Ethanol 1 mg/mL (4.3 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
9 mg/mL
Vehicle
2% DMSO+corn oil

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Costunolide Research References

  1. [1] Huang H, Park S, Zhang H, et al. Targeting AKT with costunolide suppresses the growth of colorectal cancer cells and induces apoptosis in vitro and in vivo Journal of experimental & clinical cancer research : CR (2021). PMID: 33785035 DOI: 10.1186/s13046-021-01895-w Source material
  2. [2] Whipple RA, Vitolo MI, Boggs AE, et al. Parthenolide and costunolide reduce microtentacles and tumor cell attachment by selectively targeting detyrosinated tubulin independent from NF-κB inhibition Breast cancer research : BCR (2013). PMID: 24028602 DOI: 10.1186/bcr3477 Source material
  3. [3] Choi JH, Lee KT. Costunolide-induced apoptosis in human leukemia cells: involvement of c-jun N-terminal kinase activation Biological & pharmaceutical bulletin (2009). PMID: 19801848 DOI: 10.1248/bpb.32.1803 Source material

Added to your cart

View Cart Checkout
Loading...